共0篇 平均IF=NaN (-) 更多分析

    加载中

    logo
    Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Chow Clara K,Ramasundarahettige Chinthanie,Hu Weihong,AlHabib Khalid F,Avezum Alvaro,Cheng Xiaoru,Chifamba Jephat,Dagenais Gilles,Dans Antonio,Egbujie Bonaventure A,Gupta Rajeev,Iqbal Romaina,Ismail Noorhassim,Keskinler Mirac V,Khatib Rasha,Kruger Lanthé,Kumar Rajesh,Lanas Fernando,Lear Scott,Lopez-Jaramillo Patricio,McKee Martin,Mohammadifard Noushin,Mohan Viswanathan,Mony Prem,Orlandini Andres,Rosengren Annika,Vijayakumar Krishnapillai,Wei Li,Yeates Karen,Yusoff Khalid,Yusuf Rita,Yusufali Afzalhussein,Zatonska Katarzyna,Zhou Yihong,Islam Shariful,Corsi Daniel,Rangarajan Sumathy,Teo Koon,Gerstein Hertzel C,Yusuf Salim, The lancet. Diabetes & endocrinology BACKGROUND:Data are scarce on the availability and affordability of essential medicines for diabetes. Our aim was to examine the availability and affordability of metformin, sulfonylureas, and insulin across multiple regions of the world and explore the effect of these on medicine use. METHODS:In the Prospective Urban Rural Epidemiology (PURE) study, participants aged 35-70 years (n=156 625) were recruited from 110 803 households, in 604 communities and 22 countries; availability (presence of any dose of medication in the pharmacy on the day of audit) and medicine cost data were collected from pharmacies with the Environmental Profile of a Community's Health audit tool. Our primary analysis was to describe the availability and affordability of metformin and insulin and also commonly used and prescribed combinations of two medicines for diabetes management (two oral drugs, metformin plus a sulphonylurea [either glibenclamide (also known as glyburide) or gliclazide] and one oral drug plus insulin [metformin plus insulin]). Medicines were defined as affordable if the cost of medicines was less than 20% of capacity-to-pay (the household income minus food expenditure). Our analyses included data collected in pharmacies and data from representative samples of households. Data on availability were ascertained during the pharmacy audit, as were data on cost of medications. These cost data were used to estimate the cost of a month's supply of essential medicines for diabetes. We estimated affordability of medicines using income data from household surveys. FINDINGS:Metformin was available in 113 (100%) of 113 pharmacies from high-income countries, 112 (88·2%) of 127 pharmacies in upper-middle-income countries, 179 (86·1%) of 208 pharmacies in lower-middle-income countries, 44 (64·7%) of 68 pharmacies in low-income countries (excluding India), and 88 (100%) of 88 pharmacies in India. Insulin was available in 106 (93·8%) pharmacies in high-income countries, 51 (40·2%) pharmacies in upper-middle-income countries, 61 (29·3%) pharmacies in lower-middle-income countries, seven (10·3%) pharmacies in lower-income countries, and 67 (76·1%) of 88 pharmacies in India. We estimated 0·7% of households in high-income countries and 26·9% of households in low-income countries could not afford metformin and 2·8% of households in high-income countries and 63·0% of households in low-income countries could not afford insulin. Among the 13 569 (8·6% of PURE participants) that reported a diagnosis of diabetes, 1222 (74·0%) participants reported diabetes medicine use in high-income countries compared with 143 (29·6%) participants in low-income countries. In multilevel models, availability and affordability were significantly associated with use of diabetes medicines. INTERPRETATION:Availability and affordability of essential diabetes medicines are poor in low-income and middle-income countries. Awareness of these global differences might importantly drive change in access for patients with diabetes. FUNDING:Full funding sources listed at the end of the paper (see Acknowledgments). 10.1016/S2213-8587(18)30233-X
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas. Genere Natalia,Montori Victor M Annals of internal medicine 10.7326/ACPJC-2018-168-2-008
    Pharmaceutical quality evaluation of different glimepiride brands marketed in Karachi (Pakistan): In pursuance to global issue of availability and affordability of quality medicines. Ali Sidra Kanwal,Muhammad Iyad Naeem,Siddiqui Tuba,Zaidi Syeda Hina,Masood Rida Pakistan journal of pharmaceutical sciences Availability of economical quality medicines is always required for chronic disease management. Price differences among multiple brands of a product do not essentially displays low quality for the more affordable brand, however in a few occurrences it appears. Glimepiride, an oral anti-diabetic drug, is produced by several national and multinational industries in Pakistan with considerable cost variation. The study aimed to evaluate the quality and economy of various Glimepiride brands available in Karachi, specifically of public sector hospitals. For this, eight glimepiride brands were collected and analyzed for the pharmaceutical quality using physical parameters, disintegration test, dissolution profile, spectrophotometric assay and content uniformity. Pharmacoeconomic assessment was also carried out such as availability, affordability and price variation. A profound discrepancy was observed among the prices of selected brands. All of the products found to be equivalent to the reference product except G5, the most inexpensive and highest consumed product of a public sector hospital. Study concludes that products with higher quality and lesser price can be used as a substitute to the costly brands while availability of a substandard product looks for consideration of pertinent authorities to assure the distribution of quality medicines.